Compare Dollar General Corp. (DG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Recursion Pharmaceuticals Inc — how do they compare? Dollar General Corp. trades at $123.9 (market cap $27.42B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Dollar General Corp. is far larger — about 12.8× Recursion Pharmaceuticals Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DG | RXRX | |
|---|---|---|
Market Cap | $27.42B | $2.14B |
Volume | 2,291,517 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $6.79 |
52-Week Low | $95.94 | $2.84 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $41.60B | $1.66B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DG trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong profitability with a 19.69% ROE and has beaten earnings estimates for the last three quarters. Recent news highlights margin benefits from tariff refunds and expansion of delivery services through Instacart. Cash flow from operations improved to $3.0 billion in 2025, supporting financial stability.
The outlook is positive with a consensus price target of $137.27, implying over 12% upside. Risks include competitive pressures and potential consumer spending weakness. Analyst sentiment is bullish with 55.77% buy ratings, but net income margin compression from 7.01% in 2022 to 2.77% in 2025 warrants monitoring.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
